Summary
Luye Pharma Group Ltd., an investment holding company, develops, produces, markets, and sells pharmaceutical products worldwide. The company offers Lipusu for ovarian and breast cancer; CMNa, a chemical sensitizer for cancer radiotherapy; Tiandida for ovarian or non-small cell lung cancer; Boyounuo, an injection for the treatment of various types of cancers and other solid tumors; and Xuezhikang, a lipid regulating drug for the treatment of hypercholesterolaemia. It also provides Maitongna for cerebral edema swelling by trauma or surgery, and for venous reflux disorders; Beixi, an acarbose capsule for Type 2 diabetes; Rivastigmine Transdermal Patch for the treatment of Alzheimer's disease; Fentanyl Transdermal Patch for cancer pain; Buprenorphine Transdermal Patch for chronic pain; and Seroquel and Seroquel XR for the treatment of schizophrenia and manic episodes of bipolar affective disorders, In addition, the company offers Rykindo, an injection for the treatment of schizophrenia; Tiandixin used as an adjuvant therapy for malignant tumors, hydrothorax and ascites, and respiratory infections; Yitaida for acute promyelocytic leukemia and liver cancer; Lutingnuo, a glutathione injection for toxicity and injuries caused by ionizing radiation; and Beitangning, a pioglitazone hydrochloride capsule to control blood glucose. Further, it offers Nuosen for acute upper digestive tract hemorrhage; Sailimai for the treatment of diarrhea; Apleek Transdermal Patch for contraception; Sidinuo for osteoporosis; Glucosamine hydrochloride tablets for osteoarthritis; Oulai, a compound sodium aescinate gel for local swelling; Oukai for the treatment of soft tissue swelling and venous edema; and Fengshiye for patients who have pains in bones, joints, and limbs. The company distributes and sells pharmaceutical drugs; and manufactures and sells biopharmaceutical products. Luye Pharma Group Ltd. was founded in 1994 and is headquartered in Yantai, the People's Republic of China.
History
Luye Pharma was founded in 2004 and is headquartered in Hangzhou, China. The company has years of experience in R&D and marketing pharmaceuticals in China and around the world. Luye Pharma is listed on the Shanghai Stock Exchange and has over 8,000 employees worldwide.
Mission
Luye Pharma’s mission is to provide innovative, safe and effective pharmaceutical solutions to improve the quality of life and health of individuals and communities.
Vision
Luye Pharma’s vision is to become a leading global pharmaceutical company recognized for its innovation, commitment to quality, sustainability, and excellence in customer service.
Key Team
Ms. Yuan Yuan Zhu (Exec. Director)
Mr. Yuan Chong Liu (Chief Financial Officer)
Ms. Yun Li Xue (Sr. VP & GM of Shandong Luye)
Dr. You Xin Li (Head of R&D and Sr. VP)
Ms. Mei Yi Lee ACIS, ACS, FCIS, FCS (Company Sec.)
Mr. Zhi Cheng Fan (Chief Engineer of Shandong Luye Pharmaceutical Co Ltd)
Li Ping Loh (Assistant Company Sec.)
Recognition and Awards
Luye Pharma has been recognized by numerous industry awards, including Innovator of the Year in 2020, Best Pharmaceutical Company of the Year in 2019, and Best Customer Service Provider in 2018.
References
